Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities

Nirmala Chandralega Kampan, Sue D. Xiang, Orla M. McNally, Andrew N. Stephens, Michael A. Quinn, Magdalena Plebanski

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signalling pathway has become a target for the therapy of diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130-Fc have the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments may help in the treatment of patients that would greatly benefit from IL-6 blocking therapies.

Original languageEnglish
Pages (from-to)4785-4806
Number of pages22
JournalCurrent Medicinal Chemistry
Volume25
Issue number36
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • cancer
  • IL-6
  • IL-6 receptor
  • immunotherapy
  • JAK-STAT signalling pathway
  • monoclonal antibodies
  • pro-inflammatory cytokine.
  • STAT-3

Cite this

@article{0c9b4c50a9a54daba13d3ff5830527f0,
title = "Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities",
abstract = "Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signalling pathway has become a target for the therapy of diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130-Fc have the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments may help in the treatment of patients that would greatly benefit from IL-6 blocking therapies.",
keywords = "cancer, IL-6, IL-6 receptor, immunotherapy, JAK-STAT signalling pathway, monoclonal antibodies, pro-inflammatory cytokine., STAT-3",
author = "Kampan, {Nirmala Chandralega} and Xiang, {Sue D.} and McNally, {Orla M.} and Stephens, {Andrew N.} and Quinn, {Michael A.} and Magdalena Plebanski",
year = "2018",
month = "1",
day = "1",
doi = "10.2174/0929867324666170712160621",
language = "English",
volume = "25",
pages = "4785--4806",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers",
number = "36",

}

Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer : Challenges and Opportunities. / Kampan, Nirmala Chandralega; Xiang, Sue D.; McNally, Orla M.; Stephens, Andrew N.; Quinn, Michael A.; Plebanski, Magdalena.

In: Current Medicinal Chemistry, Vol. 25, No. 36, 01.01.2018, p. 4785-4806.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer

T2 - Challenges and Opportunities

AU - Kampan, Nirmala Chandralega

AU - Xiang, Sue D.

AU - McNally, Orla M.

AU - Stephens, Andrew N.

AU - Quinn, Michael A.

AU - Plebanski, Magdalena

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signalling pathway has become a target for the therapy of diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130-Fc have the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments may help in the treatment of patients that would greatly benefit from IL-6 blocking therapies.

AB - Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signalling pathway has become a target for the therapy of diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130-Fc have the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments may help in the treatment of patients that would greatly benefit from IL-6 blocking therapies.

KW - cancer

KW - IL-6

KW - IL-6 receptor

KW - immunotherapy

KW - JAK-STAT signalling pathway

KW - monoclonal antibodies

KW - pro-inflammatory cytokine.

KW - STAT-3

UR - http://www.scopus.com/inward/record.url?scp=85058896721&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170712160621

DO - 10.2174/0929867324666170712160621

M3 - Review Article

VL - 25

SP - 4785

EP - 4806

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 36

ER -